Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis-Reference-Cited by-同舟云学术

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

Published:2017-02-14 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Honda Yasushi,Kessoku Takaomi,Ogawa Yuji,Tomeno Wataru,Imajo Kento,Fujita Koji,Yoneda Masato,Takizawa Toshiaki,Saito Satoru,Nagashima Yoji,Nakajima Atsushi

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep42477.pdf

Reference63 articles.

1. Lazo, M. & Clark, J. M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin. Liver Dis. 28, 339–350, doi: 10.1055/s-0028-1091978 (2008).

2. Day, C. P. & Saksena, S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J. Gastroenterol. Hepatol. 17, S377–S384, doi: 10.1046/j.1440-1746.17.s3.31.x (2002).

3. Promrat, K. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121–129, doi: 10.1002/hep.23276 (2010).

4. Aagaard, M. M., Siersbæk, R. & Mandrup, S. Molecular basis for gene-specific transactivation by nuclear receptors. Biochim. Biophys. Acta 1812, 824–835, doi: http://dx.doi.org/10.1016/j.bbadis.2010.12.018 (2011).

5. Kliewer, S. A. et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. 91, 7355–7359 (1994).

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment;Biomedicines;2024-08-16

2. Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease;Gastroenterology Research;2024-08

3. Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition;Biomedicine & Pharmacotherapy;2024-08

4. Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD);Life;2024-07-03

5. Utility of pemafibrate in nonalcoholic steatohepatitis model mice induced by a choline-deficient, high-fat diet and dextran sulfate sodium;Biochemistry and Biophysics Reports;2024-07